Accurate, rapid charaterization of HLA-specific antibody using luminex technology

K, Pretl; Chesterton, Kevin; Sholander, Jeffrey T.; Leffell, Mary S.

doi:10.1016/j.humimm.2003.08.201

Cited by 11 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, we have directly compared two solid phase assays for the detection of antibodies. Previous reports have suggested the Luminex assay detects HSA more frequently than the ELISA assay (34,35). We have shown that both class I and class II antibodies are detected more frequently by Luminex, although the difference in frequency was only significant for class I antibodies (p < 0.0001).…”

Section: Hla Antibodies and Scd30 In Renal Transplantationmentioning

confidence: 96%

Post-Transplant HLA class II Antibodies and High Soluble CD30 Levels are Independently Associated with Poor Kidney Graft Survival

Langan

Park

Hughes

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Hla Antibodies and Scd30 In Renal Transplantationmentioning

confidence: 96%

Post-Transplant HLA class II Antibodies and High Soluble CD30 Levels are Independently Associated with Poor Kidney Graft Survival

Langan

Park

Hughes

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

“…We found, as others have, that the bead assays are more sensitive than either ELISA with soluble HLA targets or flow cytometric crossmatches with lymphocyte targets [11][12][13]. We used the Luminex assays to evaluate of a large cohort of patients undergoing treatment with plasmapheresis and CMVIg to eliminate DSA.…”

Section: Introductionmentioning

confidence: 99%

Factors Associated With and Predictive of Persistence of Donor-Specific Antibody After Treatment With Plasmapheresis and Intravenous Immunoglobulin

2005

Self Cite

View full text Add to dashboard Cite

“…Considerable data confirm the advantage of the multiplexed technology and its applications in diverse fields of medicine, including cancer research, cytokines, gene expression, and genetic and infectious diseases. [9][10][11][12][13][14] An application of multiplexed technology in the field of autoimmunity suggests that this assay may be suitable as a sensitive screening method for detection of numerous autoantibodies in patients with autoimmune diseases. [15][16][17][18] It has been demonstrated that multiplexed technology offers a useful tool for the detection of ANA and extractable nuclear antigens in autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies

Shovman

Gilburd

Barzilai

et al. 2005

Annals of the New York Academy of Sciences

111

View full text Add to dashboard Cite

The BioPlex 2200 ANA Screen is a fully automated system that determines levels for 13 different autoimmune antibodies of established clinical significance. The objective of this study was to determine the specificity of the BioPlex 2200 ANA Screen assay and to analyze the antibody profile samples collected from healthy subjects against comparative ELISA and IIF screening methods. A total of 510 specimens were randomly selected from a cohort of apparently healthy blood bank donors. Samples were distributed to five age brackets. All samples were tested using Bio-Rad's ANA Screen kit. Specificity was compared to IIF and ELISA results. Most of the samples were found negative in all ANA screening systems (84.5% by IIF, 92.5% by BioPlex 2200 ANA Screen kit, and 94.5% by ELISA). The frequency of positive results was highest (15.5%) using IIF, in comparison to almost similar results (5.5% vs. 7.5%) achieved by ANA ELISA and BioPlex 2200 ANA Screen kits. The positive rate of autoantibodies was significantly reduced when analyzed by different combinations of ANA screen assays (from 2.35% using IIF + BioPlex ANA Screen tests to 0.98% by using all three tests). Using the BioPlex 2200 ANA Screen system, we were able to identify samples with high levels of individual antibodies: anti-dsDNA at 20-63 IU/mL, antichromatin at 4-8 AI, anti-SmRNP at 2-6 AI, and anti-RNPA at 2-4.5 AI. Importantly, from 7 IIF and ELISA positive sera, 5 of these were also BioPlex 2200 positive, suggesting that the BioPlex is seeing the samples that are of the greatest interest, using the established techniques. The specificity of the BioPlex 2200 ANA Screen analysis of 13 different analytes (dsDNA, centromere B, chromatin, Jo1, ribosomal P, RNP 68, RNP A, Scl-70, Sm, SmPNP, SS-A52, SS-A60, SS-B) is comparable (P < 0.252) to the ELISA ANA screening test. Like the ELISA, the BioPlex 2200 has a lower (P < 0.001) positive rate than IIF for the autoantibody screening.

show abstract

Accurate, rapid charaterization of HLA-specific antibody using luminex technology

Cited by 11 publications

References 0 publications

Post-Transplant HLA class II Antibodies and High Soluble CD30 Levels are Independently Associated with Poor Kidney Graft Survival

Post-Transplant HLA class II Antibodies and High Soluble CD30 Levels are Independently Associated with Poor Kidney Graft Survival

Factors Associated With and Predictive of Persistence of Donor-Specific Antibody After Treatment With Plasmapheresis and Intravenous Immunoglobulin

Evaluation of the BioPlex™ 2200 ANA Screen: Analysis of 510 Healthy Subjects: Incidence of Natural/Predictive Autoantibodies

Contact Info

Product

Resources

About